BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple (NASDAQ:AAPL) to provide cardiac monitoring services in conjunction with the Apple Heart Study.Nov 30, 2017
The Research Division of BioTelemetry
BioTelemetry Research is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.
Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:
Comprehensive Testing Services for Clinical Trials
Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 600,000 patients and subjects a year. In addition to industry-leading global cardiovascular monitoring, we provide advanced imaging services for oncology, cardiovascular, metabolic diseases, neurologic, musculoskeletal imaging.
Los Angeles, CA
Join BioTelemetry, Inc. at the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease.Jan 24-26, 2018
Publications / White Papers
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries…
Join our Vice President of Musculoskeletal and Metabolic Imaging, Jonathan Riek, PhD, and AMRA’s Chief Scientific Officer & Co-Founder, Olof Dahlqvist Leinhard, PhD, as they present alternative, noninvasive imaging methods to determine body composition.